Investing in R&D from AMR to Zika: Laying the foundation for sustainable development

24 May 2017
Geneva, Switzerland

This World Health Assembly side event is co-hosted by MMV, GHTC, PATH and TB Alliance.

Time: 12:00 - 14:00

Location: Intercontinental Hotel
Chemin du Petit-Saconnex 7-9, 1209
Genève, Switzerland

Over the past two decades, investments in global health research and development (R&D) have produced game-changing technologies to tackle some of the world’s most critical health challenges. However, despite these successes, health innovation has been sidelined in the global debate on ending poverty. Progress against existing threats like antimicrobial resistance and new public health challenges like Zika will never be possible using current technologies alone. Investments in the development of new vaccines, drugs, diagnostics, and other health tools is essential to achieving the Sustainable Development Goals, and can be a driver of economic growth.

How can governments work with each other, the private sector, and civil society to develop and scale innovative health technologies? What is needed to ensure low- and middle-income countries are driving the research agenda to tackle the diseases harming their citizens? How can investments in R&D today mitigate huge health care costs in the future?

Join us on the sidelines of the World Health Assembly for a dynamic conversation about the opportunities and challenges surrounding health R&D and the important role it can play in disrupting the cycle of poverty and poor health worldwide.

Register for this event.